Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase III studiesThe European Commission is expected to make a final decision regarding approval
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient
06.12.2021 - Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase III studiesThe European Commission is expected to make a final decision regarding approval in the near future Basel, 06 December . Seite 1
Basel, 20 October 2021 Group sales up 8%1 at constant exchange rates (CER); 6% in Swiss francsPharmaceuticals Division sales grow 5% in the third quarter and are now in line with the prior year for